Related Experiment Video
Updated: Feb 17, 2026
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
Proteins Annexin A2 and PSA in Prostate Cancer Biopsies Do Not Predict Biochemical Failure
David S Lamb1, Sven Sondhauss2, Jonathan C Dunne2
1Prostate Cancer Trials Unit, Department of Pathology and Molecular Medicine, University of Otago Wellington, Wellington, New Zealand.
Background/Aim:
We previously reported the use of mass spectrometry and western blotting to identify proteins from tumour regions of formalin-fixed paraffin-embedded biopsies from 16 men who presented with apparently localized prostate cancer, and found that annexin A2 (ANXA2) appeared to be a better predictor of subsequent biochemical failure than prostate-specific antigen (PSA).
Materials And Methods:
In this follow-up study, ANXA2 and PSA were measured using western blotting of proteins extracted from biopsies from 37 men from a subsequent prostate cancer trial.
Results:
No significant differences in ANXA2 and PSA levels were observed between men with and without biochemical failure. The statistical effect sizes were small, d=0.116 for ANXA2, and 0.266 for PSA.
Conclusion:
ANXA2 and PSA proteins measured from biopsy tumour regions are unlikely to be good biomarkers for prediction of the clinical outcome of prostate cancer presenting with apparently localized disease.
